BioPharm Insight™ Reports the Alzheimer’s Association International…

Bapineuzumab and solanezumab, among others, were up for discussion as early AD trial candidates

(PRWeb July 30, 2012)

Read the full story at http://www.prweb.com/releases/2012/7/prweb9744093.htm


Comments are closed.